浏览全部资源
扫码关注微信
1.中国中医科学院 中医基础理论研究所,北京 100700
2.首都医科大学 附属北京世纪坛医院,北京 100038
刘建鑫,博士,从事中西医结合基础研究,E-mail:jianxinliu7@163.com
马雅銮,博士,研究员,从事中医药抗炎与免疫药理研究,Tel:010-64089027,E-mail:yaluanma@163.com
纸质出版日期:2023-12-05,
网络出版日期:2023-03-25,
收稿日期:2022-12-05,
扫 描 看 全 文
刘建鑫,揭珊珊,陈冰等.基于NLRP3炎性小体和TLR4/NF-κB信号通路探讨黄连解毒汤治疗急性痛风性关节炎的作用机制[J].中国实验方剂学杂志,2023,29(23):1-7.
LIU Jianxin,JIE Shanshan,CHEN Bing,et al.Huanglian Jiedutang Treats Acute Gouty Arthritis via NLRP3 Inflammasome and TLR4/NF-κB Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(23):1-7.
刘建鑫,揭珊珊,陈冰等.基于NLRP3炎性小体和TLR4/NF-κB信号通路探讨黄连解毒汤治疗急性痛风性关节炎的作用机制[J].中国实验方剂学杂志,2023,29(23):1-7. DOI: 10.13422/j.cnki.syfjx.20230802.
LIU Jianxin,JIE Shanshan,CHEN Bing,et al.Huanglian Jiedutang Treats Acute Gouty Arthritis via NLRP3 Inflammasome and TLR4/NF-κB Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(23):1-7. DOI: 10.13422/j.cnki.syfjx.20230802.
目的
2
观察黄连解毒汤对急性痛风性关节炎(AGA)模型小鼠炎性损伤的影响,探讨黄连解毒汤治疗AGA的作用机制。
方法
2
40只雄性C57BL/6J小鼠随机分为正常组、模型组、秋水仙碱组和黄连解毒汤组。采用踝关节注射单钠尿酸盐(MSU)晶体混悬液建立小鼠AGA模型,给药组分别给予黄连解毒汤水煎液(5 g·kg
-1
)和秋水仙碱(0.83 mg·kg
-1
),每天测量小鼠右踝关节肿胀程度,7 d后苏木素-伊红(HE)染色检测踝关节组织病理改变。另外40只C57BL/6J小鼠同样分组处理,造模18 h后,取右踝关节,实时荧光定量聚合酶链式反应(Real-time PCR)检测关节炎症因子白细胞介素(IL)-1
β
、肿瘤坏死因子(TNF)-
α
、IL-6和NOD样受体蛋白3(NLRP3)炎性小体NLRP3、凋亡相关斑点样蛋白(ASC)、胱天蛋白酶-1(Caspase‑1)mRNA的表达;酶联免疫吸附测定法(ELISA)检测炎症因子IL-1
β
、TNF-
α
和IL-6含量;蛋白免疫印迹法(Western bolt)检测NLRP3炎性小体和Toll样受体4/核转录因子-
κ
B(TLR4/NF-
κ
B)信号通路蛋白的表达。
结果
2
与正常组比较,模型组小鼠右踝关节显著肿胀(
P
<
0.01),HE染色观察到踝关节明显异物肉芽肿,其间有炎症细胞浸润,黄连解毒汤干预后可以缓解踝关节肿胀(
P
<
0.05,
P
<
0.01),异物肉芽肿减小。与正常组比较,模型组踝关节组织中炎症因子IL-1
β
含量和IL-1
β
、TNF-
α
、IL-6 mRNA表达显著升高(
P
<
0.01),NLRP3炎性小体、Caspase‑1 mRNA表达明显升高(
P
<
0.05,
P
<
0.01),NLRP3、Caspase-1、TLR4和NF-
κ
B蛋白表达明显升高(
P
<
0.05,
P
<
0.01);与模型组比较,黄连解毒汤干预明显降低炎症因子IL-1
β
、TNF-
α
、IL-6和NLRP3炎性小体、Caspase‑1 mRNA表达(
P
<
0.05,
P
<
0.01),显著降低关节组织中炎症因子IL-1
β
、TNF-
α
和IL-6含量(
P
<
0.01),下调NLRP3、Caspase‑1、TLR4、NF-
κ
B蛋白的表达(
P
<
0.05,
P
<
0.01)。
结论
2
注射MSU晶体导致AGA小鼠关节局部炎性免疫损伤,黄连解毒汤干预减轻炎性免疫损伤,可能与其调控NLRP3炎性小体和TLR4/NF-
κ
B信号通路相关。
Objective
2
To observe the effect of Huanglian Jiedutang on the inflammatory injury in the mouse model of acute gouty arthritis (AGA) and to explore the mechanism of Huanglian Jiedutang in treating AGA.
Method
2
Forty male C57BL/6J mice were randomized into blank, model, colchicine (0.83 mg·kg
-1
), and Huanglian Jiedutang (5 g·kg
-1
) groups. The mouse model of AGA was established by injecting monosodium urate (MSU) crystals into the ankle joint. The swelling degree of the right ankle joint of each mouse was measured every day for 7 days, and the pathological changes of the ankle joint were detected by hematoxylin-eosin (HE) staining after 7 days. The other 40 C57BL/6J mice were grouped as above. After 18 hours of modeling, the right ankle joint was collected, and real-time polymerase chain reaction was employed to measure the mRNA levels of interleukin (IL)-1
β
, tumor necrosis factor (TNF)-
α
, IL-6, NOD-like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), and Caspase-1. The expression levels of IL-1
β
, TNF-
α
, and IL-6 were measured by the enzyme-linked immunosorbent assay. Western blot was employed to determine the protein levels of NLRP3 inflammasome, Toll-like receptor 4 (TLR4), and nuclear factor-
κ
B (NF-
κ
B).
Result
2
Compared with the blank group, the model group showed swelling right ankle joint (
P
<
0.01), obvious foreign body granuloma in the ankle joint with inflammatory cell infiltration. After the treatment with Huanglian Jiedutang, the ankle joint swelling was relieved (
P
<
0.05,
P
<
0.01), and the size of foreign body granuloma was reduced. Compared with the blank group, the model group showed up-regulated mRNA levels of IL-1
β
, TNF-
α
, and IL-6 in the ankle joint tissue (
P
<
0.01), up-regulated mRNA levels of NLRP3 and Caspase-1 in the NLRP3 inflammasome (
P
<
0.05,
P
<
0.01), and up-regulated protein levels of NLRP3, Caspase-1, TLR4, and NF-
κ
B (
P
<
0.05,
P
<
0.01). Huanglian Jiedutang down-regulated the mRNA levels of IL-1
β
, TNF-
α
, IL-6, NLRP3, and Caspase-1 (
P
<
0.05,
P
<
0.01) and the protein levels of IL-1
β
, TNF-
α
, IL-6, NLRP3, Caspase-1, TLR4, and NF-
κ
B (
P
<
0.05 or
P
<
0.01).
Conclusion
2
Injecting MSU crystal resulted in local inflammatory injury of the joints in the mouse model of AGA. The treatment with Huanglian Jiedutang may alleviate the inflammatory injury by regulating the NLRP3 inflammasome and TLR4/NF-
κ
B signaling pathway.
急性痛风性关节炎黄连解毒汤NOD样受体蛋白3(NLRP3)炎性小体Toll样受体4/核转录因子-κB(TLR4/NF-κB)信号通路
acute gouty arthritisHuanglian JiedutangNOD-like receptor protein 3 (NLRP3) inflammasomeToll-like receptor 4/nuclear factors-κB (TLR4/NF-κB) signaling pathway
DALBETH N,GOSLING A L,GAFFO A,et al.Gout[J].Lancet,2021,397(10287):1843-1855.
PAN Z,HUANG M,FANG M,et al.Socioeconomic differences in hyperuricemia and gout:A systematic review and Meta-analysis[J].Endocrine,2020,69(2):286-293.
中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020(1):1-13.
周蜜,王一飞,袁佳沁,等.急性痛风性关节炎免疫学发病机制研究进展[J].世界临床药物,2018,39(11):779-782.
BULLETIN D T.Latest guidance on the management of gout[J].BMJ,2018,362:k2893-k2898.
章晓云,曾浩,李华南,等.痛风性关节炎的发病机制及中医药治疗研究进展[J].中国实验方剂学杂志,2022,28(11):256-267.
董颖,刘保光,许二平.黄连解毒汤抗炎作用与临床应用研究进展[J].中国实验方剂学杂志,2021,27(12):245-250.
郭璐露.黄连解毒汤联合来氟米特治疗类风湿性关节炎41例临床观察[J].湖南中医杂志,2020,36(1):30-32.
姜海欧,赵彩凤,刘振功,等.优化黄连解毒汤配合放血疗法治疗急性痛风性关节炎疗效研究[J].中国实用医药,2018,13(19):13-15.
陈长江,王宗涛,谭华儒.黄连解毒汤加味配合金黄膏治疗痛风关节炎126例[J].中国中医急症,2008(8):1153-1154.
REBER L L,MARICHAL T,SOKOLOVE J,et al.Contribution of mast cell-derived interleukin-1β to uric acid crystal-induced acute arthritis in mice[J].Arthritis Rheumatol,2014,66(10):2881-2891.
刘丽兰,关宝生,张淑红,等.痛风炎症反应中NLRP3炎性体的激活机制[J].中医临床研究,2022,14(6):128-130,136.
CODERRE T J,WALL P D.Ankle joint urate arthritis in rats provides a useful tool for the evaluation of analgesic and anti-arthritic agents[J].Pharmacol Biochem Behav,1988,29(3):461-466.
吕军,方和金,吴涛.一种改进的痛风性关节炎大鼠模型制备方法[J].中国现代医学杂志,2014,24(18):17-21.
刘建鑫,揭珊珊,赵雨坤,等.急性痛风性关节炎小鼠模型制备方法的改良[J].中国中医基础医学杂志,2022,28(5):714-717,791.
李利生,史源泉,龚其海.淫羊藿苷抗尿酸钠诱导的大鼠急性痛风性关节炎作用[J].中国实验方剂学杂志,2017,23(11):134-138.
DALBETH N,CHOI H K,JOOSTEN L A B,et al.Gout[J].Nat Rev Dis Primers,2019,5(1):69-86.
董鹏,宋慧.痛风发病机制研究进展[J].基础医学与临床,2015,35(12):1695-1699.
陈琳,周静,马武开,等.中医治疗痛风性关节炎的研究进展[J].风湿病与关节炎,2020,9(5):73-76.
党万太,周京国,谢文光.从《金匮要略》探讨痛风“代谢-炎症-免疫”发病机制[J].辽宁中医杂志,2014,41(10):2090-2093.
邓中甲.方剂学[M].北京:中国中医药出版社,2003:100.
徐晓辰,丁焕发,刘淑娟,等.血清IL-1β、IL-6、IL-18及TNF-α水平在急性痛风性关节炎镇痛治疗不同时间动态变化的研究[J].中国医学创新,2016,13(24):4-10.
SOLOMON D H,GLYNN R J,MACFADYEN J G,et al.Relationship of interleukin-1β blockade with incident gout and serum uric acid levels:Exploratory analysis of a randomized controlled trial[J].Ann Intern Med,2018,169(8):535-542.
JANSSEN C A,OUDE VOSHAAR M A H,VONKEMAN H E,et al.Anakinra for the treatment of acute gout flares:A randomized,double-blind,placebo-controlled,active-comparator,non-inferiority trial[J].Rheumatology (Oxford),2019,doi:10.1093/rheumatology/key402http://dx.doi.org/10.1093/rheumatology/key402.
BUSSO N,SO A.Mechanisms of inflammation in gout[J].Arthritis Res Ther,2010,12(2):206-214.
贺雅萌,王镁.中药通过调节炎症因子治疗痛风的研究概述[J].环球中医药,2022,15(4):713-718.
刘淑娟,丁焕发,徐晓辰,等.急性痛风性关节炎患者血清IL-1β、IL-6、IL-18及TNF-α水平的研究[J].中国医药指南,2016,14(16):3-5.
JOOS H,LEUCHT F,RIEGGER J,et al.Differential interactive effects of cartilage traumatization and blood exposure in vitro and in vivo[J].Am J Sports Med,2015,43(11):2822-2832.
SO A K,MARTINON F.Inflammation in gout:Mechanisms and therapeutic targets[J].Nat Rev Rheumatol,2017,13(11):639-647.
张团庄,宋渊,何志军,等.中药干预NLRP3炎症小体治疗骨关节相关疾病研究进展[J].中国实验方剂学杂志,2023,doi:10.13422/j.cnki.syfjx.20230508http://dx.doi.org/10.13422/j.cnki.syfjx.20230508.
PETER S,RU LB,ANYA S,et al.Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation[J].Arthritis Rheum,2005,52(9):2936-2946.
RU L B,GARY S,KENNETH P,et al.TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation[J].J Immunol,2005,174(8):5016-5023.
欧阳香,丁婷,杨海艳,等.痛风性关节炎发病机制相关信号通路的研究进展[J].中药药理与临床,2021,37(4):234-240.
0
浏览量
43
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构